Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
There’s stuff going on…. about patents.
In the text of the half year report, this appears to be buried…
“ The patent estate covering SRA737 was recently expanded by the granting of a patent in the US (no. 11596637) that describes the combination of SRA737 with a PARP inhibitor and its effectiveness in inhibiting tumour growth.”
I say buried, because I don’t recall this being mentioned in the presentation. But I may have missed it. Apologies if so.
http://www.sareum.com/files/4616/7947/3777/230322_Half-Year_results_FINAL.pdf
It appears that the patent was indeed *recently* granted: Date of Patent: Mar 7, 2023 and I see that another board member picked up on this recently.
https://patents.justia.com/patent/11596637
So… what’s going on with patents? Yet another board member suggested a while ago that patent handover might not be straightforward, and despite Parker’s previous assertions, this might be proving to be the case.
Yet the patents appear to be valuable, so valuable as to hold the key to unlocking the commercialisation of 737.
“ would a big pharma welcome a competitor like 737 in triple combination therapy up against its already paid for pipeline?”
I don’t believe that’s the point.
At least one of the compounds that 737 has been trialled with is now a generic. But patenting that generic in combo with 737 could (and has been) patented.
So as I understand it, it’s dusting down an old product for which the patent has expired and novating the patent as a combo. As a result - the combo becomes a serious revenue earner.
Ahfam, you missed this one:
3:40 “as well as the potential to treat autoimmune diseases such as psoriasis, which will be our initial focus, there’s still the opportunity to investigate the treatment of respiratory symptoms arising from viral infection such as covid 19 and our phase 1a trial is expected to enable all applications of SD -1801”.
It’s an early / pre-clinical deal similar to the Pronai deal for 737, yes?
But here’s the good news…. 737 has moved on and is a magnitude more valuable, thanks to Sierra doing a bunch of work on it for free.
So here’s the better strategy…. pursue a deal for 737 and keep 1801 in-house for a better, later deal.
I don’t know where you’re getting your data from, Aberystwyth, but LSE is telling me:
Vol Sold 459
Vol Bought 54,651
And both 15k trades are clearly buys. Both well above the mid-point so there’s no ambiguity at all.
No problem at all, horse. It just looks like poor proof reading, or complete lack of it. Or poor oversight when the article is prepared for publication. Maybe even leaving the info in the template from the previous article. Anyway, very poor when you’re in an industry where accuracy of data is paramount.